PURPOSE AND METHODS: By the mid 1980s, tamoxifen alone was considered standard adjuvant therapy for postmenopausal women with node-positive, estrogen receptor (ER)- or progesterone receptor (PgR)-positive breast cancer. From 1984 through 1990, 705 eligible postmenopausal women with node-positive, ER- or PgR-positive breast cancer were randomized to a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study that compared tamoxifen 30 mg by mouth daily for 2 years (TAM) versus TAM plus chemotherapy with all-intravenous cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 given every 21 days for eight cycles (CMF). RESULTS: There were no significant differences in overall survival, recurrence-free survival, locoregional recurrence-free survival, or distant recurrence-free survival between the two treatment arms. However, there was significantly greater severe toxicity, which included leukopenia (P < .0001), nausea and vomiting (P < .0001), and thromboembolic events (P < .0001), as well as significantly more mild or greater toxicity, which included thrombocytopenia (P = .04), anemia (P = .02), infection (P = .0004), mucositis (P = .0001), diarrhea (P = .0001), and neurologic toxicity (P = .006), in women who received TAM plus CMF. CONCLUSION: The addition of CMF to TAM adds no benefit and considerable toxicity in this group of women.
RCT Entities:
PURPOSE AND METHODS: By the mid 1980s, tamoxifen alone was considered standard adjuvant therapy for postmenopausal women with node-positive, estrogen receptor (ER)- or progesterone receptor (PgR)-positive breast cancer. From 1984 through 1990, 705 eligible postmenopausal women with node-positive, ER- or PgR-positive breast cancer were randomized to a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study that compared tamoxifen 30 mg by mouth daily for 2 years (TAM) versus TAM plus chemotherapy with all-intravenous cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 given every 21 days for eight cycles (CMF). RESULTS: There were no significant differences in overall survival, recurrence-free survival, locoregional recurrence-free survival, or distant recurrence-free survival between the two treatment arms. However, there was significantly greater severe toxicity, which included leukopenia (P < .0001), nausea and vomiting (P < .0001), and thromboembolic events (P < .0001), as well as significantly more mild or greater toxicity, which included thrombocytopenia (P = .04), anemia (P = .02), infection (P = .0004), mucositis (P = .0001), diarrhea (P = .0001), and neurologic toxicity (P = .006), in women who received TAM plus CMF. CONCLUSION: The addition of CMF to TAM adds no benefit and considerable toxicity in this group of women.
Authors: Pelagia G Tsoutsou; Yazid Belkacemi; Joseph Gligorov; Abraham Kuten; Hamouda Boussen; Nuran Bese; Michael I Koukourakis Journal: Oncologist Date: 2010-11-01
Authors: Raimund Jakesz; Hellmut Samonigg; Michael Gnant; Ernst Kubista; Dieter Depisch; Roland Kolb; Brigitte Mlineritsch; Hans-Jörg Mischinger; Rainer-Christian Menzel; Peter Steindorfer; Werner Kwasny; Christoph Tausch; Michael Stierer; Susanne Taucher; Michael Seifert; Hubert Hausmaninger Journal: Ann Surg Date: 2003-04 Impact factor: 12.969
Authors: M Napolitano; F Keime-Guibert; A Monjour; C Lafitte; A Ameri; P Cornu; P Broët; J Y Delattre Journal: J Neurooncol Date: 1999 Impact factor: 4.130
Authors: Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman B Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne Journal: Lancet Date: 2009-12-10 Impact factor: 79.321
Authors: Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons Journal: Oncology Date: 2012-09-05 Impact factor: 2.935